59.50 +0.11 (0.19%)
After hours: 4:38PM EST
|Bid||59.16 x 1800|
|Ask||59.50 x 800|
|Day's Range||58.36 - 65.35|
|52 Week Range||22.22 - 74.00|
|Beta (3Y Monthly)||3.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
Shares of the biotech company are rising in early trading after the company proposed offering an additional 4.25 million common shares for sale.
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
Shares of Crispr Therapeutics jumped Tuesday after the biotech company's gene-editing approach to sickle cell disease and beta thalassemia, both blood diseases, showed early promise.
Shares of CRISPR Therapeutics AG fell in after-hours trading Tuesday after the gene-therapy company announced a public offering of 4.25 million shares. The decline followed a sharp rise in the regular session sparked by positive initial results in an early-stage trial of a gene therapy for blood diseases including sickle cell anemia.
Crispr Therapeutics AG (NASDAQ: CRSP ) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's ...
The gene-editing technique known as Crispr/Cas9 produced promising early-stage results, sending shares of Crispr Therapeutics and Vertex Pharmaceuticals higher.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
Advanced Micro Devices Inc. (AMD) jumped 81 cents to $37.52 on 67 million shares traded Wednesday. Amarin Corp. PLC (AMRN) followed through on Wednesday, up 55 cents to $21.49 after popping 23% on Tuesday. An FDA advisory committee is scheduled to meet today to help decide the fate of the company’s fish-derived cardiovascular drug.
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.
Current ratio is a popular way for investors to assess the health of a stock’s balance sheet. Current ratio is a measure of a company’s ability to pay its current liabilities and obligations due within ...
State Street, General Electric and Raytheon are among the local companies with executives speaking at the Future Investment Initiative.
BTIG sees Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s decision to exercise its options to in-license three additional targets as one that further integrated the operations of the two companies, fueling speculation that Vertex could end up buying Crispr.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 352.63% and 3252.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?